Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation

Next Previous
X
Search
Trial Profile

A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Garsorasib (Primary) ; Cetuximab
  • Indications Carcinoma; Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors InventisBio

    • Most Recent Events

    • 21 Jan 2024 Planned primary completion date changed from 1 Nov 2024 to 15 Apr 2024.
    • 04 Jan 2024 Status changed from recruiting to active, no longer recruiting.
    • 24 Oct 2023 Results (As of April 17, 2023, n=29) assessing safety and efficacy of D-1553 combined with cetuximab in KRAS G12C mutated CRC, presented at the 48th European Society for Medical Oncology Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top